Cure Today8h
Breyanzi Improves Responses in R/R Indolent B-Cell Non-Hodgkin Lymphoma
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
Cure Today1d
Phase 2 Trial of Firi-Cel CAR T-Cell Therapy Discontinued in Lymphoma
The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...
Targeted Oncology9d
Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite ...
Daily20h
FDA Approves Mirdametinib for Neurofibromatosis Type 1
The US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli) for adults and children aged 2 and older with ...
oncnursingnews1d
Amezalpat Receives FDA Fast Track Designation for Hepatocellular Carcinoma
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
FiercePharma3d
Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead
With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...
Medscape4d
Radiation Intensification Enhances Response in Rectal Cancer
Radiation dose intensification improves pathologic complete response rates in locally advanced rectal cancer but also leads ...
Cancer Therapy Advisor9d
Certain Sarcoma Patients Remain Progression-Free After Stopping Larotrectinib
Patients received larotrectinib for anywhere from 1 month to more than 87 months. The overall response rate was 87%, which included 47 complete responses and 32 partial responses. Seven patients had ...